Biocon Limited (BIOCON) announced that its Pertuzumab biosimilar secured EMA CHMP approval, marking a significant milestone in expanding access to HER2-posit.
Biocon Limited (BIOCON) announces the U.S. launch of Yesafili™, a biosimilar to Regeneron’s Eylea® 2 mg, expanding access to eye treatment.
Biocon Limited (BIOCON) publishes pivotal clinical data supporting the effectiveness of Yesafili™, a biosimilar to Eylea®.